Ibrexafungerp for Acute Yeast: Four Trial Checks

Before asking about a different antifungal, establish what is causing the symptoms. CDC¹ guidance says itching, soreness and discharge are not specific to yeast. Persistent symptoms after an over-the-counter treatment, or symptoms returning within two months, need clinical assessment and testing.¹

Trial treatment

VANISH 303 tested one acute episode: oral ibrexafungerp 300 mg twice in one day versus placebo. Of 376 randomized participants, 371 received treatment. Most were under 50.²

Complete response

At days 8–14, complete resolution of signs and symptoms without additional treatment occurred in 95/190 versus 28/100: 50% versus 28%. The difference was 22 percentage points, 95% confidence interval 10.2–32.8. Missing responses counted as failures.³⁴

A negative culture was a separate endpoint.²

Why the denominator matters

The paper used 188/98 for efficacy. FDA³ required restoring the analysis-plan population: culture-positive participants who received treatment, without extra symptom-entry exclusions.²³

Follow-up was about 25 days, without active comparison or prevention testing. SCYNEXIS funded it; authors disclosed commercial ties.²

Treatment-related diarrhea occurred in 55/247 versus 5/124.²

For the separate maintenance question, see the monthly CANDLE results.

Current prescribing checks

The July 2026 US label contraindicates Brexafemme during pregnancy and in people allergic to ibrexafungerp. For those who can become pregnant, the prescriber must verify pregnancy status before starting. Effective contraception is needed during an acute course and for four days after the last dose.⁴

The label lists 300 mg, two 150 mg tablets, approximately 12 hours apart for one day for an acute infection, with or without food. Strong CYP3A inhibitors require a lower prescribed dose; strong or moderate CYP3A inducers should be avoided. Take the medicine and supplement list to the pharmacist rather than adjusting the dose yourself. Diarrhea, nausea, abdominal pain, dizziness and vomiting are common adverse reactions in acute-treatment studies.⁴

Availability also needs checking. ASHP’s⁵ October 14, 2026 bulletin reports no available presentations and no estimated return date for temporarily unavailable Brexafemme. That was still the posted bulletin when checked October 19. Ask the pharmacist and prescriber to agree on an available treatment.⁵

Bring the dates of symptoms, test results, treatments already tried and any pregnancy possibility. Before leaving, ask whom to contact if symptoms persist and whether another examination or culture would be needed.

Down There, Decoded includes “The Sorter” and a symptom log recording product names, dates and what happened afterward. The book places first-time, persistent and recurring changes in the clinician-assessment category. That preparation can help you describe the episode without assuming the diagnosis.